Clinical trial
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00052273 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00052273 |
|---|---|
| Title | LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult, Solid Tumor |
| Intervention type | Drug |
| Interventions | capecitabine, enzastaurin hydrochloride |
| Enrollment | 16 |
| Start date | Dec 1, 2002 |
| Primary completion | Nov 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: